Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A snapshot of the year-to-date total market return for 2024, outlining performance drivers and practical implications for investors.
28,420 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Oklo stock fell further as traders digested quarterly results and a new regulatory filing. This article breaks down w...
Two major price cuts from Chinese AI labs are changing the economics of frontier AI. For crypto traders and funds, ch...
As AI features roll out and iPhone upgrades loom, investors face a nuanced picture: potential stock downside from wea...
Markets moved sharply lower after kevin warsh comments send fresh jitters through stocks and bonds. Traders weigh a p...
In a pivotal moment, kevin warsh debuts chair at the Federal Reserve, with policymakers keeping the federal funds rat...
Big bets on AI infrastructure are reshaping markets. This article dives into whether the Magnificent Seven's plan spe...
Nio is signaling a major profitability milestone with its first adjusted profit, but the real impact for investors de...
A high-stakes clash between two top AI firms and the Pentagon exemplifies growing concerns about governance, safety, ...
RESO and CMLS have ended talks to form a unified group after a year of discussions. The decision preserves separate m...
As AI investment expands across big-cap tech and startups, ACM Research and Ouster emerge as practical additions to s...
Oil prices hovered around $111 per barrel on May 15, 2026, signaling jitters over supply and demand in a volatile year.